surpass cvot tirzepatide 🫀 EASD 2025: (SURPASS-CVOT) Dulaglutide head-to-head showdown: ✓ Noninferior for MACE ✓ 16% ↓ all-cause mortality ✓ Superior in A1C & weight loss Tirzepatide confirms its broad cardiometabolic edge. #EASD2025 # Tirzepatide #GLP1 In patients with type 2

SKU: 56245071736

Pay in 4 interest-free payments of $6.14 Learn more

Live Spec

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS CVOT trial results: https: nej.md 4qd5rLx New SURPASS CVOT Ad Hoc Analysis: Tirzepatide outperforms dulaglutide for reducing cardiorenal risks in T2D patients : r Zepbound SURPASS CVOT shows tirzepatide delivers comparable cardiovascular safety to dulaglutide in patients with type 2 diabetes and established ASCVD, reinforcing the shift toward therapies that optimize whole cardiometabolic systems. As outcome datasets grow Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program Cardiovascular Diabetology Springer Nature Link AHA 25: SURPASS CVOT:Tirzepatide vs Dulaglutide for Heart Failure in T2D A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre specified exploratory analyses of the SURPASS CVOT trial The Lancet Diabetes & Endocrinology

Store: tnailspamo.com · Domain: tnailspamo.com